

PDH Kinase Inhibitor Screening Based on Quantitation of PDH E₁α Phosphoserines 232, 293 or 300

Rev.2

INTRODUCTION

This protocol describes high throughput screens for inhibitors (or activators) of pyruvate dehydrogenase kinase (PDK) isoforms PDK1, PDK2, PDK3 or PDK4 by measuring the levels of PDH E₁α phosphorylation after exposure of immunocaptured PDH to each kinase in the presence and absence of test compounds. Each set of measurements can be performed on 96 samples.

Although a variety of generic approaches can be used to measure protein kinase activity, the protocol described here is unique as it allows one to screen rapidly for inhibitors/activators of each of the 4 isoforms of PDK by monitoring PDK site-specific phosphorylation of PDH purified from any tissue or cell type of interest, including whole tissue/cell extracts of human, bovine, rat or mouse cells, tissues or mitochondria. The PDH of interest is first quickly purified and immobilized in microplate arrays by microscale immunocapture and then exposed to the PDK of choice in the presence or absence of PDK inhibitors/activators. Phosphorylation levels of specific PDH E₁α serines (232, 293 or 300) are then measured to determine whether or not test compounds inhibited, activated, or had no effect on PDK activity. Unaltered PDKs phosphorylate PDH at a defined rate, resulting in quantitative phosphorylation of PDH at these sites and concomitant inactivation of PDH activity. In contrast, drug-induced inhibition of PDK activity blocks PDK-mediated phosphorylation of PDH. Thus, compounds of interest can be added to the PDK phosphorylation reaction and their effect on PDH phosphorylation can be analyzed, making this product an ideal screening tool for inhibitors or activators of PDKs. Optimized conditions of the PDK-mediated phosphorylation reactions are described that result in fully phosphorylated PDH E₁α serines (232, 293 and/or 300), and fully inactivated PDH (Figures 2, 3, 4 and 5) when unaltered PDK is used.

The main advantage of this protocol is that PDH is purified by immunocapture in individual microwells and the endogenous specific and non-specific kinases originally associated with the enzyme are washed away. Therefore, the subsequent PDK-mediated phosphorylation reaction is dependent only on the activity of exogenously added PDK. Further advantages are as follows: (1) a variety of PDH sources can be used, (2) there is no need to biochemically purify PDH laboriously or to depend on a commercial enzyme, and (3) the phosphorylation reaction is stopped rapidly by a simple wash. Finally, if desired, the PDH can first be fully dephosphorylated after immunocapture, but prior to exposure to PDKs to maximize the PDK effect. Dephosphorylation can be accomplished with the use of specific recombinant PDH phosphatases (PDP1 or PDP2) available from MitoSciences (MSP45 and MSP46, respectively), and then the PDPs can be washed away prior the PDK-mediated phosphorylation of immunocaptured PDH.

REGULATION OF PDH ACTIVITY

The pyruvate dehydrogenase complex (PDH) (E.C.1.2.4.1) is the key regulatory enzyme of cellular metabolism, in that it links the TCA cycle and subsequent oxidative phosphorylation with glycolysis and gluconeogenesis as well as with both lipid and amino acid metabolism. PDH is a large complex of three enzymes, pyruvate dehydrogenase (E₁), dihyrolipoyl acyltransferase (E₂), and dihydrolipoyl dehydrogenase (E₃), and one structural protein (E₂/E₃ binding protein). In total the enzyme is composed of five different polypeptide chains, E₁α, E₁β, E₂, E₃ and E₂/E₃BP with 30:30:60:12:12 stoichiometry. PDH catalyzes irreversible oxidative decarboxylation of pyruvate to acetyl coenzyme A. The activity of PDH is negatively regulated by reversible phosphorylation of the E₁α subunit. The phosphorylation is catalyzed by four PDH kinase isozymes (E.C.2.7.11.2), PDK 1, 2, 3 and 4. The dephosphorylation that activates PDH is catalyzed by two PDH phosphatases (E.C. 3.1.3.43), PDP 1 and 2.

The PDH kinases are Serine/Threonine protein kinases. They are ATP-dependent enzymes that are bound to the E₂ domain of PDH. The PDH kinases phosphorylate three specific sites of the E₁α subunit (the phospho-Serine positions are given through this text with respect to the human protein): Site 1 (Ser 293), Site 2 (Ser 300) and Site 3 (Ser 232), thus inhibiting the enzyme activity (Figure 1). Each of the

PDH Protocol #4 – PDH Kinase Inhibitor Screening Based on Quantitation of PDH E₁α Phosphoserines 232, 293 or 300

kinases has different reactivity towards the three phosphorylation sites. While under normal dietary conditions PDK2 is the predominant isoform in skeletal muscle, the PDK4 is induced by exercise and diet as well as by starvation. This kinase is aberrantly upregulated in insulin resistant diabetes. The levels of PDK4 are sensitive to inhibitors of the PPAR transcription factors. In contrast, the levels of PDK1 are sensitive to O₂ levels and under regulation by the transcription factor HIF1. An increase in the level of PDK1 is a key part of Warburg effect, a switch from oxidative to glycolytic ATP production that characterizes cancer cells. Because of the manifold roles of PDKs in physiology and disease, there is considerable interest in identifying drugs that regulate PDK activities.




Figure 1. Schematic representation of the PDK-dependent phosphorylation and PDP-dependent dephosphorylation of PDH. Phosphorylation occurs at Serines 232, 293, and 300 of the human E₁α subunits. Phosphorylation results in inactivation of PDH, dephosphorylation results in activation of PDH.

MitoSciences offers a comprehensive line of PDH-related assays and tools, including all four PDH kinases, both PDH phosphatases, PDH activity microplate assays and PDH protein quantity microplate assays. For convenience, these tools are available combined in kits and described in additional protocols.

See the MitoSciences PDH Playbook for an overview of applications possible using MitoSciences PDH assays and tools. This protocol (MitoSciences PDH Protocol #4) describes how to screen for inhibitors and/or activators of each of the four PDH kinases by measuring the levels of PDH E₁α phosphorylation at serines 232, 293 and 300 after exposure of immunocaptured PDH to each kinase in the presence and absence of test compounds. A complementary protocol (PDH Protocol #3) describes how to screen for inhibitors and/or activators of the 4 PDKs by measurement of PDK-mediated inhibition of PDH activity. The two protocols (PDH activity-based and PDH phosphorylation-based) can be performed in parallel to obtain a comprehensive analysis of the effects of potential inhibitors and/or activators of PDKs.

PDH Protocol #4 – PDH Kinase Inhibitor Screening Based on Quantitation of PDH E₁α Phosphoserines 232, 293 or 300**MATERIALS**

Most of the components required in this protocol are provided in the PDH Enzyme Activity Microplate Assay Kit (MitoSciences Cat. #MSP18). The recipes for the components not included in MSP18 are provided in Appendix A of this protocol. **Note – When using this protocol with MSP18, it REPLACES the standard MSP18 protocol.**

Item	Quantity	Storage
Detergent (component of MSP18)	2 x 1 mL	4°C
20X Buffer (component MSP18)	15 mL	4°C
96-well Pre-coated Microplate (component of MSP18)	1 EA	4°C
Phosphatase Inhibitor (PI)	1.5 mL	4°C
5X Stabilizer	13 mL	4°C
20X Wash Buffer	20 mL	4°C
10X Blocking Solution	5 mL	4°C
20X PhosphoDetect™ Anti-PDH-E ₁ α (pSer ²³²) Rabbit pAb (EMD Chemicals, cat. #AP1063)	50 µg	-20°C
20X PhosphoDetect™ Anti-PDH-E ₁ α (pSer ²⁹²) Rabbit pAb (EMD Chemicals, cat. #AP1062)	50 µg	-20°C
20X PhosphoDetect™ Anti-PDH-E ₁ α (pSer ³⁰⁰) Rabbit pAb (EMD Chemicals, cat. #AP1064)	50 µg	-20°C
20X HRP Label	1 mL	4°C
Development Solution	20 mL	4°C
50X ATP	0.2 mL	-80°C
Choice of PDKs:		
PDK1 (MSP41)	50 µg	-80°C
PDK2 (MSP42)	50 µg	-80°C
PDK3 (MSP43)	50 µg	-80°C
PDK4 (MSP44)	50 µg	-80°C

Avoid repeated freeze/thaw cycles of frozen components and keep them on ice when not in storage. Store the remaining reagents at 4°C

ADDITIONAL MATERIALS REQUIRED

- Spectrophotometer plate reader (Molecular Dynamics SpectraMax recommended) capable of measuring absorbance at 650 nm, preferably in a kinetic mode.
- Method for determining protein concentration
- Multichannel pipette

PDH Protocol #4 – PDH Kinase Inhibitor Screening Based on Quantitation of PDH E₁α Phosphoserines 232, 293 or 300

- Deionized water
- PBS (phosphate buffered saline) – for recipe see Appendix

ASSAY PROTOCOL

This protocol has four steps:

A. Sample Preparation.

PDH-containing extracts are prepared.

B. PDH Immunocapture.

PDH from the sample is immunocaptured in the desired number of wells.

C. Phosphorylation Reactions.

The immunocaptured PDH is phosphorylated with the PDK of choice in the presence (or absence) of a compound being tested as a modulator of PDK activity in three wells in parallel.

D. Phosphorylation Measurements.

Levels of PDH E₁α phospho-Serine 232 are measured in the first well, levels of PDH E₁α phospho-Serine 293 are measured in the second well and levels of PDH E₁α phospho-Serine 300 are measured in the third well.

Below are recommended amounts of sample materials. These amounts were carefully chosen to fit within the linear range of PDH E₁α Phospho-Serine 232, 293 and 300 signals (Fig. 6). For a control sample, purified bovine heart mitochondria (MS802) are available from MitoSciences.

Sample type	Recommended amount
Purified mitochondria	50 µg/well (0.25 mg/mL)
Tissue homogenates	125 µg/well (0.625 mg/mL)
Cultured cells	500 µg/well (2.50 mg/mL)

This protocol describes the use of sufficient PDK1, 2, 3 or 4 to perform 96 phosphorylation reactions with each enzyme, with each able to phosphorylate and fully inhibit PDH immunocaptured using recommended amounts of materials (50 µg of bovine heart mitochondria (available individually as MS802, Bovine Heart Mitochondria IP Control), corresponding to 1 milliunit of porcine PDH, Sigma P7032, 125 µg of rat or mouse heart tissues, or 500 µg of HepG2 cells).

Since each sample is analyzed for Phospho-Serine 232, 293 and 300 quantities in three separate wells, the MSP18 PDH immunocapture kit can be used for complete analysis of 32 samples in the 96 wells provided. The microplate can be broken into 12 separate 8-well strips. For convenience, considering the above, the volumes in this protocol are given for analysis of multiples of three strips (24 wells) allowing complete analysis of 8 samples.

Note – Be completely familiar with protocol and protocol notes before beginning the assay. Do not deviate from the specified protocol steps or optimal results may not be obtained.

PDH Protocol #4 – PDH Kinase Inhibitor Screening Based on Quantitation of PDH E₁α Phosphoserines 232, 293 or 300

A. Sample Preparation

1. Determine the sample protein concentration using a standard method such as BCA method (Pierce).
2. Adjust the protein concentration of the sample, according to the sample type used, by dilution in PBS, as specified below. *See Note 1 for addition of protease inhibitors.*

Sample type	Protein concentration (mg/mL)
Purified mitochondria	5.3
Tissue homogenates	23.7
Cultured cells	15.0

3. Prepare the extraction according to the table below. Mix components immediately after the addition of the detergent. *It is imperative to keep the ratio of components of extraction as specified below. Below are suggested volumes for preparation of sufficient amounts for loading of three strips (24 wells).*

Component	Purified mitochondria	Tissue homogenates	Cultured cells
Sample (μL)	285	237.5	1,350
Detergent (μL)	15	12.5	150
Total Volume (μL)	300	250	1,500
Final Protein Concentration (mg/mL)	5.0	22.5	13.5

4. Incubate on ice for 10 minutes.
5. Centrifuge in a tabletop centrifuge for 10 minutes at 4°C as specified below. Carefully collect and save the supernatant. Discard the pellet.

Sample type	RCF (x g)
Purified mitochondria	5,000
Tissue homogenates	1,000
Cultured cells	1,000

PDH Protocol #4 – PDH Kinase Inhibitor Screening Based on Quantitation of PDH E₁α Phosphoserines 232, 293 or 300

6. Prepare the Dilution Buffer as specified below.

No. of Plate Strips	dH ₂ O (mL)	20X Buffer (mL)	Total (mL)
3	5.7	0.3	6
6	11.4	0.6	12
9	17.1	0.9	18
12	22.8	1.2	24

7. Dilute the samples' supernatants in the Dilution Buffer to recommended concentration according to the table below.

Sample type	Recommended concentration (mg/mL)
Purified mitochondria	0.25 (20X dilution)
Tissue homogenates	0.625 (36X dilution)
Cultured cells	2.50 (5.4X dilution)

B. PDH Immunocapture

- A. Plate loading. Add 200 μ L/well of diluted sample prepared in Step 7 of Section A.
B. Incubate microplate for 2.5 hours at room temperature.

C. Phosphorylation Reactions

1. Prepare 1X Reaction/Wash Buffer according to the table below.

1X Reaction/Wash Buffer					
No. of Plate Strips	dH ₂ O (mL)	20X Buffer (mL)	5X Stabilizer (mL)	PI (mL)	Total (mL)
3	29	2	8	0.8	40
6	58	4	16	1.6	80
9	88	6	24	2.4	120
12	117	8	32	3.2	160

PDH Protocol #4 – PDH Kinase Inhibitor Screening Based on Quantitation of PDH E₁α Phosphoserines 232, 293 or 300

- Prepare 2X Compound of Interest Working Stock. *It is recommended to load six wells with each compound of interest to obtain duplicate values of Phospho-Serine 232, 293 and 300 quantities. Below are suggested volumes for preparation of sufficient amounts for loading of six wells.*

2X Compound of Interest Working Stock						
No. of wells	Water (μL)	20X Buffer (μL)	5X Stabilizer (μL)	Compound of Interest (μL)	Total (μL)	
6	525-X	35	140	X	700	

- Prepare PDK Working Stock following the appropriate table below. Prepare only the amount needed. NOTE: It is important to load the PDKs at sub-saturating levels so reductions in PDK phosphorylation (due to the action of a potential PDK inhibitor) can be detected easily. The formulation below yields final amounts of PDK1, 2 or 4 at 1 μg/well, and PDK3 at 0.05 μg/well, as these are rate-limiting amounts for many sample types (see Figures 2-5). It is recommended that PDK titration curves as shown in Figures 2-5 be run for any novel source of PDH used as a capture target in this assay.

2X PDK1, 2 or 4 Working Stock							
No. of Plate Strips	dH ₂ O (mL)	20X Buffer (mL)	5X Stabilizer (mL)	PI (μL)	PDK1, 2 or 4 (μL)	50X ATP (μL)	Total (mL)
3	1.73	0.13	0.52	104	17	104	2.6
6	3.45	0.26	1.04	208	35	208	5.2
9	5.17	0.39	1.56	312	52	312	7.8
12	6.90	0.52	2.08	416	69	416	10.4

2X PDK3 Working Stock							
No. of Plate Strips	dH ₂ O (mL)	20X Buffer (mL)	5X Stabilizer (mL)	PI (μL)	PDK3 (μL)	50X ATP (μL)	Total (mL)
3	1.72	0.13	0.52	104	9	104	2.6
6	3.44	0.26	1.04	208	17	208	5.2
9	5.15	0.39	1.56	312	26	312	7.8
12	6.86	0.52	2.08	416	35	416	10.4

- Empty the wells of the microplate by turning it over and shaking out any remaining liquid. Blot the plate face down on paper towel.
- Add 300 μL/well of 1X Reaction/Wash Buffer to wash the wells.
- Repeat the steps 6. and 7. one more time for a total of 2 wash steps.

PDH Protocol #4 – PDH Kinase Inhibitor Screening Based on Quantitation of PDH E₁α Phosphoserines 232, 293 or 300

7. Again, empty the wells of the microplate by turning it over and shaking out any remaining liquid. Blot the plate face down on paper towel.
8. Add promptly 100 μ L of 2X Compound of Interest Working Stock and 100 μ L of 2X PDK Working Stock into each well. Mix immediately. See Note 2 for phosphorylation reaction controls. For suggested microplate layout, see Step 8 of Section D.
9. Incubate the plate for 10 min at 30°C.

D. Quantity measurement

1. Prepare 1X Wash Buffer by adding 15 mL of 20X Wash Buffer to 185 mL of deionized water.
2. Prepare 1X Blocking Buffer according to the table below. Prepare only the amount needed.

1X Blocking Buffer			
No. of Plate Strips	1X Wash Buffer (mL)	10X Blocking Solution (mL)	Total Volume (mL)
3	10.8	1.2	12.0
6	21.6	2.4	24.0
9	32.4	3.6	36.0
12	43.2	4.8	48.0

3. Prepare each of the 1X Phospho-PDH Serine 232, 293 and 300 Detector Antibodies according to the table below. Each of the 1X Detector Antibodies is needed only for one third of wells. Prepare only the amount needed.

1X Detector Antibody			
No. of Plate Strips	1X Blocking Buffer (mL)	20X Detector Antibody (μ L)	Total Volume (mL)
1	1.67	83	1.75
2	3.33	167	3.50
3	5.00	250	5.25
4	6.67	333	7.00

4. Empty the wells of the microplate by turning it over and shaking out any remaining liquid. Blot the plate face down on paper towel.
5. Add 300 μ L/well of 1X Reaction/Wash Buffer to wash the wells.
6. Repeat the steps 2. and 3. two more times for a total of 3 wash steps.

PDH Protocol #4 – PDH Kinase Inhibitor Screening Based on Quantitation of PDH E₁α Phosphoserines 232, 293 or 300

- Again, empty the wells of the microplate by turning it over and shaking out any remaining liquid. Blot the plate face down on paper towel.
- Add 200 μL/well of 1X 232 Detector Antibody to the first set of wells, 200 μL/well of 1X 293 Detector Antibody to the second set of wells, and 200 μL/well of 1X 300 Detector Antibody to the third set of wells, as shown in a layout below.

	1X 232 Detector Antibody				1X 293 Detector Antibody				1X 300 Detector Antibody			
	1	2	3	4	5	6	7	8	9	10	11	12
A	1	1	9	9	1	1	9	9	1	1	9	9
B	2	2	10	10	2	2	10	10	2	2	10	10
C	3	3	11	11	3	3	11	11	3	3	11	11
D	4	4	12	12	4	4	12	12	4	4	12	12
E	5	5	13	13	5	5	13	13	5	5	13	13
F	6	6	14	14	6	6	14	14	6	6	14	14
G	7	7	Con1	Con1	7	7	Con1	Con1	7	7	Con1	Con1
H	8	8	Con2	Con2	8	8	Con2	Con2	8	8	Con2	Con2

Recommended Microplate Layout for compounds of interest numbered 1-14, Control 1 and Control 2, measured for phospho-Serine 232 (purple), phospho-Serine 293 (blue) and phospho-Serine 300 (red) quantities in duplicates. To make these measurements, the first set of wells (columns 1-4) is incubated with 1X 232 Detector Antibody, the second set of wells (columns 5-8) is incubated with 1X 293 Detector Antibody, and the third set of wells (columns 9-12) is incubated with 1X 300 Detector Antibody.

- Incubate the plate for 1 hour at room temperature.
- Prepare 1X HRP Label according to the table below. Prepare only the amount needed.

1X HRP Label			
No. of Plate Strips	1X Blocking Buffer (mL)	20X HRP Label (mL)	Total Volume (mL)
3	5	0.25	5.25
6	10	0.50	10.50
9	15	0.75	15.75
12	20	1.00	21.00

PDH Protocol #4 – PDH Kinase Inhibitor Screening Based on Quantitation of PDH E₁α Phosphoserines 232, 293 or 300

11. Empty the wells of the microplate by turning it over and shaking out any remaining liquid. Blot the plate face down on paper towel.
12. Add 300 µL/well of 1X Wash Buffer to wash the wells.
13. Again, empty the wells of the microplate by turning it over and shaking out any remaining liquid. Blot the plate face down on paper towel.
14. Add to each well 200 µL of 1X HRP Label.
15. Incubate the plate for 1 hour at room temperature.
16. Empty the wells of the microplate by turning it over and shaking out any remaining liquid. Blot the plate face down on paper towel.
17. Add 300 µL/well of 1X Wash Buffer to wash the wells.
18. Repeat steps 15. and 16. three more times for a total of 4 wash steps.
19. Again, empty the wells of the microplate by turning it over and shaking out any remaining liquid. Blot the plate face down on paper towel.
20. Add 200 µL/well of Development Solution. Avoid bubbles. Any bubbles in the wells should be popped with a fine needle as rapidly as possible.
21. Promptly place the plate into a spectrophotometer and begin microplate reading using the following parameters. (Alternatively, an endpoint measurement can be made by stopping the reaction at a user defined time by addition of 100 µL/well of 1 N HCl and recording absorbance at 450 nm.)

Mode:	Kinetic
Wavelength:	650 nm
Time:	30 min
Interval:	20 sec - 1 min
Shaking:	Shake between readings

22. Save data and analyze them as described in the Data Analysis section.

PROTOCOL NOTES

1. If desired, samples can be supplemented with protease inhibitors, such as Protease Inhibitor Cocktail (Sigma P8340) to minimize nonspecific proteolysis during the sample preparation.
2. Each experiment should include following two phosphorylation reaction controls using the PDH source of interest. Control 1 (mock-PDK phosphorylated sample), this is a sample treated in the absence of PDK and in the absence of compound of interest. Control 2 (mock-compound of interest phosphorylated sample), this is a sample treated with PDK in the absence of compound of interest.

**PDH Protocol #4 – PDH Kinase Inhibitor Screening Based on
Quantitation of PDH E₁α Phosphoserines 232, 293 or 300**

**PDH Protocol #4 – PDH Kinase Inhibitor Screening Based on
Quantitation of PDH E₁α Phosphoserines 232, 293 or 300**

DATA ANALYSIS

1. The background phospho-Serine level, detected with a particular detector antibody, is equal the phospho-Serine level of the mock-PDK phosphorylated sample (Control 1). Control 1 is the sample treated in the absence of PDK and in the absence of compound of interest.
2. The maximum phospho-Serine level, detected with a particular detector antibody, is equal the phospho-Serine level of the mock-compound of interest phosphorylated sample (Control 2). Control 2 is the sample treated with PDK in the absence of compound of interest.
3. If a compound of interest (included in the phosphorylation reaction) does not inhibit the PDK-catalyzed phosphorylation of PDH E₁α, the phospho-Serine level, detected with a particular detector antibody, is equal to the phospho-Serine level of Control 2.
4. If a compound of interest (included in the phosphorylation reaction) inhibits the PDK-catalyzed phosphorylation of PDH E₁α, the phospho-Serine level, detected with a particular detector antibody, is lower than the phospho-Serine level of Control 2.
5. If a compound of interest (included in the phosphorylation reaction) fully inhibits the PDK-catalyzed phosphorylation of PDH E₁α, the phospho-Serine level, detected with a particular detector antibody, is equal to the phospho-Serine level of Control 1.
6. Then the inhibitory effect of a compound of interest on the PDK-catalyzed phosphorylation of PDH E₁ α is inversely proportional to the PDH E₁α, the phospho-Serine level measured and can be expressed as follows:

$$\text{Effect of COI (\%)} = 100 - 100 \times (P\text{-Ser}^{\text{COI}} - P\text{-Ser}^{\text{Con1}}) / (P\text{-Ser}^{\text{Con2}} - P\text{-Ser}^{\text{Con1}})$$

Abbreviation are as follows:

COI = Compound of Interest

P-Ser = Phospho-Serine

Con1 = Control 1

Con2 = Control 2

7. Thus, a compound of interest will have no inhibitory effect on PDK-catalyzed phosphorylation when the *Effect of COI* is 0 %. A compound of interest will have maximum inhibitory effect on PDK-catalyzed phosphorylation when the *Effect of COI* is 100 %. The *Effect of COI* can be determined for each of the phosphorylation site (232, 293 and 300).

**PDH Protocol #4 – PDH Kinase Inhibitor Screening Based on
Quantitation of PDH E₁α Phosphoserines 232, 293 or 300****APPENDIX A. Recipes for Required Components**

Phosphatase Inhibitor (PI)		
<ul style="list-style-type: none">• NaF (EM Science SX-0550-3), FW 41.99• Deionized Water		
Component	Grams per 100 mL	Concentration (M)
NaF	2.10	0.5
Dissolve NaF in deionized water. Adjust volume to 100 mL. Store at -20°C.		

5X Stabilizer		
<ul style="list-style-type: none">• Albumin, from bovine serum (Sigma A4503)• Deionized water		
Component	Grams per Liter	Concentration (mg/mL)
Albumin, from bovine serum	50	50
Dissolve Albumin in water. Adjust volume to 1000 mL. Filter Sterilize and store at 4°C		

50X ATP		
<ul style="list-style-type: none">• Adenosine 5'-triphosphate, disodium salt (Sigma A2383), FW 551.1• Deionized water		
Component	Grams per 10 mL	Concentration (mM)
Adenosine 5'-triphosphate	0.551	100
Dissolve Adenosine 5'-triphosphate in deionized water. Adjust volume to 10 mL. Store aliquoted at -20°C.		

PDH Protocol #4 – PDH Kinase Inhibitor Screening Based on Quantitation of PDH E₁α Phosphoserines 232, 293 or 300
PDK of choice (MitoSciences)

- PDK3, MitoSciences MSP43. **Note – This stock PDK3 is at 0.5 µg/µL and must be diluted to make the component PDK3 at 0.15 µg/µL**
- PDK1, MitoSciences MSP41. Note – This stock PDK1 is at 1.5 µg/µL and can be used as is for the component PDK1 at 1.5 µg/µL
- PDK2, MitoSciences MSP42. Note – This stock PDK2 is at 1.5 µg/µL and can be used as is for the component PDK2 at 1.5 µg/µL
- PDK4, MitoSciences MSP44. Note – This stock PDK4 is at 1.5 µg/µL and can be used as is for the component PDK4 at 1.5 µg/µL
- Dilution Buffer (10 mM Na-PO₄, 250 mM NaCl, 30% glycerol, 5 mM DTT, 0.5 mM EDTA, 0.05% Triton X-100, pH 7.5 with HCl)

PDK of choice	Grams per mL	Concentration (µg/µL)
PDK1	NA	1.50
PDK2	NA	1.50
PDK3	NA	0.15
PDK4	NA	1.50

Avoid repeated freeze/thaw cycles of the enzymes and keep on ice when not in storage.
 Thaw on ice the stock of the Human Recombinant PDK.
 Equilibrate the Dilution Buffer to 4°C.
 Dilute the Human Recombinant PDK in the Dilution Buffer to the desired concentration.
 Aliquot to pre-chilled tubes.
 Store at -80°C.

20X Wash Buffer

- Trizma Base (Sigma T6066), FW 121.14
- MgCl₂ · 6H₂O (VWR 1483-01) FW 203.31
- NaF (EM Science SX-0550-3) FW 41.99
- n-Dodecyl-β-D-Maltopyranoside (Anatrace D310S), FW 510.6

Component	Grams per Liter	Concentration
Trizma Base	121.14	1 M
MgCl ₂	4.07	20 mM
NaF	8.4	200 mM
n-Dodecyl-β-D-Maltopyranoside	3.00	0.3 %

Dissolve components in deionized water. Adjust pH with HCl to 7.5. Adjust volume to 1 L.
 Store at -20°C.

PDH Protocol #4 – PDH Kinase Inhibitor Screening Based on Quantitation of PDH E₁α Phosphoserines 232, 293 or 300

10X Blocking Solution		
<ul style="list-style-type: none"> 10X Blocking Buffer (Sigma B6429) 		
Component	Grams per L	Concentration (%)
10X Blocking Buffer	NA	100
Store at RT.		

20X Phospho-PDH Ser²³² Detector Antibody		
<ul style="list-style-type: none"> Phospho-PDH Serine²³² Polyclonal Antibody (EMD Chemicals, cat. #AP1063. Note – This concentrated stock must be diluted to make the 20X component) Antibody Diluent (2 mg/mL BSA, 50 mM Tris-HCl pH 7.5, 0.015% n-Dodecyl-β-D-Maltopyranoside) 		
Component	Grams per L	20X Concentration (μg/mL)
PhosphoDetect™ Anti-PDH-E ₁ α (pSer ²³²) Rabbit pAb	NA	10
Dilute the antibody in the Antibody Diluent. Store at 4°C.		

20X Phospho-PDH Ser²⁹³ Detector Antibody		
<ul style="list-style-type: none"> Phospho-PDH Serine²⁹³ Polyclonal Antibody (EMD Chemicals, cat. #AP1062. Note – This concentrated stock must be diluted to make the 20X component) Antibody Diluent (2 mg/mL BSA, 50 mM Tris-HCl pH 7.5, 0.015% n-Dodecyl-β-D-Maltopyranoside) 		
Component	Grams per L	20X Concentration (μg/mL)
PhosphoDetect™ Anti-PDH-E ₁ α (pSer ²⁹³) Rabbit pAb	NA	10
Dilute the antibody in the Antibody Diluent. Store at 4°C.		

20X Phospho-PDH Ser³⁰⁰ Detector Antibody		
<ul style="list-style-type: none"> Phospho-PDH Serine³⁰⁰ Polyclonal Antibody (EMD Chemicals, cat. #AP1064. Note – This concentrated stock must be diluted to make the 20X component) Antibody Diluent (2 mg/mL BSA, 50 mM Tris-HCl pH 7.5, 0.015% n-Dodecyl-β-D-Maltopyranoside) 		
Component	Grams per L	20X Concentration (μg/mL)
PhosphoDetect™ Anti-PDH-E ₁ α (pSer ³⁰⁰) Rabbit pAb	NA	10
Dilute the antibody in the Antibody Diluent. Store at 4°C.		

PDH Protocol #4 – PDH Kinase Inhibitor Screening Based on Quantitation of PDH E₁α Phosphoserines 232, 293 or 300

20X HRP Label		
<ul style="list-style-type: none"> Goat-Anti-Rabbit-IgG (H+L)-HRP (Southern Biotech 4050-05) Guardian Peroxidase Conjugate Stabilizer/Diluent (Thermo Fisher 37548) 		
Component	Grams per Liter	Concentration (µg/mL)
Goat-Anti-Rabbit-IgG (H+L)-HRP	NA	10
Dilute the label in Guardian Peroxidase Conjugate Stabilizer/Diluent. Store at 4°C.		

Development Solution		
<ul style="list-style-type: none"> Sure Blue TMB Microwell Peroxidase Substrate (KPL 52-00-03) 		
Component	Grams per L	Concentration (%)
Sure Blue	NA	100
Store at 4°C.		

PBS (Phosphate Buffered Saline)		
<ul style="list-style-type: none"> KH₂PO₄, Potassium Phosphate Monobasic (Sigma P0662), FW 136.09 Na₂HPO₄·7H₂O, Sodium Phosphate Dibasic Heptahydrate (Sigma S9390), FW 268.07 KCl, Potassium Chloride (Sigma P3111), FW 74.56 dH₂O NaCl, Sodium chloride (Sigma S3014), FW 58.44 		
For 1 L PBS		
0.2 g	KH ₂ PO ₄	(1.4 mM)
2.2 g	Na ₂ HPO ₄	(8 mM)
0.2 g	KCl	(2.7 mM)
8.2 g	NaCl	(140 mM)
Add dry components to 0.9 L H ₂ O. The pH value should be 7.3, adjust if necessary. Add H ₂ O to 1 L.		

PDH Protocol #4 – PDH Kinase Inhibitor Screening Based on Quantitation of PDH E₁α Phosphoserines 232, 293 or 300

SUPPORTING DATA




Figure 2. PDKs phosphorylate and fully inactivate bovine PDH. As described in this protocol, PDH immunocaptured from 50 μ g of bovine heart mitochondria was treated with indicated amounts of recombinant PDKs in the presence of ATP (in red) or in the absence of ATP (in blue). PDH activities (first row) were measured with the use of MSP18. PDH E₁ α Phospho-Serine 232 (second row), 293 (third row), and 300 (fourth row) quantities were measured with the use of MitoSciences anti-E₁ α phosphosite specific mAbs as described in this protocol.

Note that: (1) 2 μ g of PDK1 are sufficient to fully phosphorylate Serine 232, 293 and 300, and fully inactivate the PDH, (2) 2 μ g of PDK2 are sufficient to fully phosphorylate Serine 293 and 300, and fully inactivate the PDH, (3) 0.1 μ g of PDK3 is sufficient to fully phosphorylate Serine 293 and 300, and fully inactivate the PDH, and (4) 2 μ g of PDK4 are sufficient to fully phosphorylate Serine 293 and 300, and fully inactivate the PDH. Also note that only PDK1 can phosphorylate the Serine 232 of PDH E₁ α . In addition, note that the treatment with ATP alone (in the absence of PDKs) when compared to the treatment in the absence of ATP does not substantially reduce the PDH activity, indicating absence of endogenous kinases.

PDH Protocol #4 – PDH Kinase Inhibitor Screening Based on Quantitation of PDH E₁α Phosphoserines 232, 293 or 300




Figure 3. PDKs phosphorylate and fully inactivate rat PDH. Extracts of rat heart homogenate were dephosphorylated with PDP1 to ensure maximum activity. Then, as described in the PROTOCOL, PDH was immunocaptured from 125 μ g of the dephosphorylated rat heart homogenate and it was treated with indicated amounts of recombinant PDKs in the presence of ATP. PDH activities (first row) were measured with the use of MSP18. PDH E₁ α Phospho-Serine 232 (second row), 293 (third row), and 300 (fourth row) quantities were measured with the use of MitoSciences anti-E₁ α phosphosite specific mAbs as described in this protocol.

Note that: (1) 2 μ g of PDK1 are sufficient to fully phosphorylate Serine 232 and 293, and fully inactivate the PDH, (2) 2 μ g of PDK2 are sufficient to fully phosphorylate Serine 293 and fully inactivate the PDH, (3) 0.1 μ g of PDK3 is sufficient to fully phosphorylate Serine 293 and 300, and fully inactivate the PDH, and (4) 2 μ g of PDK4 are sufficient to fully phosphorylate Serine 293 and 300, and fully inactivate the PDH E₁ α .

PDH Protocol #4 – PDH Kinase Inhibitor Screening Based on Quantitation of PDH E₁α Phosphoserines 232, 293 or 300




Figure 4. PDKs phosphorylate and fully inactivate mouse PDH. Extracts of mouse heart homogenate were dephosphorylated with PDP1 to ensure maximum activity. Then, as described in this protocol, PDH was immunocaptured from 125 μg of the dephosphorylated mouse heart homogenate and it was treated with indicated amounts of recombinant PDKs in the presence of ATP (in red) or in the absence of ATP (in blue). PDH activities (first row) were measured with the use of MSP18. PDH E₁ α Phospho-Serine 232 (second row), 293 (third row), and 300 (fourth row) quantities were measured with the use of MitoSciences anti-E₁α phosphosite specific mAbs as described in this protocol.

Note that: (1) 2 μg of PDK1 are sufficient to fully phosphorylate Serine 232 and 293, and fully inactivate the PDH, (2) 2 μg of PDK2 are sufficient to fully phosphorylate Serine 293 and 300, and fully inactivate the PDH, (3) 0.1 μg of PDK3 is sufficient to fully phosphorylate Serine 293 and fully inactivate the PDH, and (4) 2 μg of PDK4 are sufficient to fully phosphorylate Serine 293 and 300, and fully inactivate the PDH. Also note that only PDK1 can phosphorylate the Serine 232 of PDH E₁ α. In addition, note that the treatment with ATP alone (in the absence of PDKs) when compared to the treatment in the absence of ATP does not substantially reduce the PDH activity, indicating absence of endogenous kinases.

PDH Protocol #4 – PDH Kinase Inhibitor Screening Based on Quantitation of PDH E₁α Phosphoserines 232, 293 or 300




Figure 5. The recombinant human PDKs phosphorylate and fully inactivate human PDH. Extracts of HepG2 cells were dephosphorylated with PDP1 to ensure maximum activity. Then, as described in this protocol, PDH was immunocaptured from 500 μg of the dephosphorylated HepG2 cells and it was treated with indicated amounts of recombinant PDKs in the presence of ATP (in red) or in the absence of ATP (in blue). PDH activities (first row) were measured with the use of MSP18. PDH E₁α Phospho-Serine 232 (second row), 293 (third row), and 300 (fourth row) quantities were measured with the use of MitoSciences anti-E₁α phosphosite specific mAbs as described in this protocol.

Note that: (1) 2 μg of PDK1 are sufficient to fully phosphorylate Serine 232 and 293, and fully inactivate the PDH, (2) 2 μg of PDK2 are sufficient to fully phosphorylate Serine 293 and fully inactivate the PDH, (3) 0.1 μg of PDK3 is sufficient to fully phosphorylate Serine 293 and 300, and fully inactivate the PDH, and (4) 2 μg of PDK4 are sufficient to fully phosphorylate Serine 293 and 300, and fully inactivate the PDH. Also note that only PDK1 can phosphorylate the Serine 232 of PDH E₁α. In addition, note that the treatment with ATP alone (in the absence of PDKs) when compared to the treatment in the absence of ATP does not substantially reduce the PDH activity, indicating absence of endogenous kinases.

PDH Protocol #4 – PDH Kinase Inhibitor Screening Based on Quantitation of PDH E₁α Phosphoserines 232, 293 or 300






Figure 6. Determination of a linear range of PDH E₁α Phospho-Serine 232, 293 and 300 signals of bovine, rat, mouse and human PDH. Extracts of bovine heart mitochondria, rat heart homogenate, mouse heart homogenate and human HepG2 cells were treated with PDK1 (in green), PDK3 (in red) or PDP1 (in blue), and PDH was immunocaptured from indicated amounts of materials. PDH E₁α Phospho-Serine 232, 293 and 300 levels were measured using MitoSciences anti-E₁α phosphosite specific mAbs as described in this protocol.

PDH Protocol #4 – PDH Kinase Inhibitor Screening Based on Quantitation of PDH E₁α Phosphoserines 232, 293 or 300**FLOW CHART**

For quick reference only. Be completely familiar with previous details of this document before performing the assay.



**PDH Protocol #4 – PDH Kinase Inhibitor Screening Based on
Quantitation of PDH E₁α Phosphoserines 232, 293 or 300**



MICROPLATE MS _____

_____/_____/_____/_____